Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 GeneticVariation disease BEFREE Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. 30447300 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 GeneticVariation disease BEFREE Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. 29596070 2018
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 Biomarker disease BEFREE Finally, we found that primary cells from a patient with KRAS-mutant juvenile myelomonocytic leukemia displayed reduced colony formation in response to JAK2 inhibition. 27418650 2016
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 Biomarker disease BEFREE In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia. 27157043 2016
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 Biomarker disease BEFREE Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. 20955399 2010
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 GeneticVariation disease BEFREE Other mutations of putative pathogenetic relevance in MPDs include: JAK2V617F in PV, ET, and PMF; JAK2 exon 12 mutations in PV; MPLW515L/K in PMF and ET; KITD816V in SM; FIP1L1-PDGFRA in CEL-SM; rearrangements of PDGFRB in CEL-CMML and FGFR1 in stem cell leukemia-lymphoma syndrome; and RAS/PTPN11/NF1 mutations in JMML. 17351342 2007
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 GeneticVariation disease BEFREE In addition, Bcr/Abl-negative classic myeloproliferative disorders are characterized by recurrent JAK2(V617F) mutations, whereas other mutations affecting the RAS signaling pathway molecules have been associated with juvenile myelomonocytic leukemia. 16781478 2006
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.080 GeneticVariation disease LHGDN JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. 16079889 2005